Mohammed Alo։ How Low Should LDL Go in Secondary Prevention of Cardiovascular Disease
Mohammed Alo, Fellow of the American College of Cardiology at American College of Cardiology, shared a post on LinkedIn:
“For years, cardiology has debated a simple question:
If you already have heart disease, how low should your LDL cholesterol go?
The new Ez-PAVE trial gives us one of the clearest answers yet.
This randomized trial followed 3,048 patients with established atherosclerotic cardiovascular disease and compared 2 LDL targets:
- LDL less than 55 mg/dL vs LDL less than 70 mg/dL
After 3 years, the lower-target group had significantly fewer cardiovascular events:
- 6.6% vs 9.7%
- Hazard ratio: 0.67
That translates to:
- 33% relative risk reduction
- 3.1% absolute risk reduction
Why does this matter?
Because this was not just a ‘drug trial.’
It was a target-to-target trial.
It asked the real-world question physicians and patients face every day:
Is aiming for below 55 actually better than aiming for below 70?
The answer appears to be yes.
A few key takeaways:
- Even a modest LDL difference mattered
- Fewer heart attacks and repeat procedures occurred in the lower-target group
- Safety was reassuring
- Many high-risk patients in the real world are still nowhere near these targets
My take as a cardiologist:
If you already have coronary disease, prior stents, bypass surgery, stroke, TIA, or peripheral artery disease, an LDL of 65 or 70 should not automatically be considered ‘good enough.’
For most secondary prevention patients, under 55 mg/dL is the right goal.
The therapies already exist:
- High-intensity statins
- Ezetimibe
- PCSK9 inhibitors when needed
The issue is no longer whether lower is better.
The issue is whether we are actually getting patients there.”

Stay updated with Hemostasis Today.
-
Jul 14, 2026, 15:03Heghine Khachatryan: Phase III Trial Results Support BAFF-R Inhibition in Corticosteroid-Refractory ITP
-
Jul 14, 2026, 14:51Nathan Connell: ISTH 2026 Highlights the Power of Lifelong Collaboration
-
Jul 14, 2026, 14:42Wolfgang Miesbach: VOYAGER1 Highlights Progress Toward Injection-Free Care in Hemophilia A
-
Jul 14, 2026, 12:08Elvira Grandone: Finding the Right LMWH Dose for Pregnant Patients Suffering From DVT
-
Jul 14, 2026, 12:05Eloïse Laouenan: From Washington to Paris – Join GETBO at ISTH 2026
-
Jul 14, 2026, 12:02Louise St. Germain Bannon: Our first ISTH regulatory session at ISTH 2026
-
Jul 14, 2026, 11:21Malwina Maliszewska: Advancing Coagulation Diagnostics at ISTH 2026
-
Jul 14, 2026, 11:07Mary Cushman: Honoring Outstanding Mentorship at ISTH 2026
-
Jul 14, 2026, 10:53Maha Othman: Advancing the Management of Inherited Thrombocytopenias at ISTH 2026